mTORC1 — Drug Target

All drugs that target mTORC1 — marketed and clinical-stage. Includes 2 drug classes acting on this target.

Drug classes

mTOR inhibitor · mTORC1 inhibitor

Phase 3 pipeline (2)

• Drug: Everolimus · Grupo Espanol de Tumores Neuroendocrinos · mTOR inhibitor · Oncology
  Everolimus inhibits mTOR (mammalian target of rapamycin), a key protein kinase that regulates cell growth and proliferation.
• AZD0486 · AstraZeneca · mTORC1 inhibitor · Oncology
  AZD0486 is a selective inhibitor of the mechanistic target of rapamycin complex 1 (mTORC1) that suppresses protein synthesis and cell proliferation in cancer cells.